2. UroToday Home
  3. Categories

Prostate Cancer

Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells.

Cellular senescence can exert dual effects in tumors, either suppressing or promoting tumor progression. The senescence-associated secretory phenotype (SASP), released by senescent cells, plays a crucial role in this dichotomy.

Identification of genes that promote PI3K pathway activation and prostate tumour formation.

We have performed a functional in vivo mutagenesis screen to identify genes that, when altered, cooperate with a heterozygous Pten mutation to promote prostate tumour formation. Two genes, Bzw2 and Eif5a2, which have been implicated in the process of protein translation, were selected for further validation.

Testosterone Recovery after Androgen Deprivation Therapy in Prostate Cancer: Building a Predictive Model.

To analyze the variability, associated actors, and the design of nomograms for individualized testosterone recovery after cessation of androgen deprivation therapy (ADT).

A longitudinal study was carried out with 208 patients in the period 2003 to 2019.

Adaption and National Validation of a Tool for Predicting Mortality from Other Causes Among Men with Nonmetastatic Prostate Cancer - Beyond the Abstract

To avoid over- and under-treatment of prostate cancer, providers should balance the risk of death from prostate cancer against other causes (non-prostate cancer mortality). Less than a quarter of urologists and radiation oncologists use a tool to estimate non-prostate cancer mortality and, without standard tools, provider risk estimates are often inaccurate and may be biased. Specifically, overreliance on age can cause treatment to be withheld from older healthy men and given to younger men in poor health.

Multi-Institutional Analysis of Metastasis-Directed Therapy with or without Androgen Deprivation Therapy in Oligometastatic Castration-sensitive Prostate Cancer - Beyond the Abstract

In the evolving landscape of oligometastatic castration-sensitive prostate cancer (omCSPC) treatment, the integration of systemic hormonal therapy and metastasis-directed therapy (MDT) represents a crucial area of investigation.

The Lancet Commission on prostate cancer: planning for the surge in cases.

Lancet (London, England). 2024 Apr 04 [Epub ahead of print]

Nicholas D James, Ian Tannock, James N'Dow, Felix Feng, Silke Gillessen, Syed Adnan Ali, Blanca Trujillo, Bissan Al-Lazikani, Gerhardt Attard, Freddie Bray, Eva Compérat, Ros Eeles, Omolara Fatiregun, Emily Grist, Susan Halabi, Áine Haran, Daniel Herchenhorn, Michael Hofman, Mohamed Jalloh, Stacy Loeb, Archie MacNair, Brandon Mahal, Larissa Mendes, Masood Moghul, Caroline Moore, Alicia Morgans, Michael Morris, Declan Murphy, Vedang Murthy, Paul L Nguyen, Anwar Padhani, Charles Parker, Hannah Rush, Mark Sculpher, Howard Soule, Matthew R Sydes, Derya Tilki, Nina Tunariu, Paul Villanti, Li-Ping Xie

Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK.

Mediator kinase inhibition reverses castration resistance of advanced prostate cancer.

Mediator kinases CDK19 and CDK8, pleiotropic regulators of transcriptional reprogramming, are differentially regulated by androgen signaling but both kinases are upregulated in castration-resistant prostate cancer (CRPC).

Overexpression of Fibroblast Activation Protein (FAP) in stroma of proliferative inflammatory atrophy (PIA) and primary adenocarcinoma of the prostate.

Fibroblast activation protein (FAP) is a serine protease upregulated at sites of tissue remodeling and cancer that represents a promising therapeutic and molecular imaging target. In prostate cancer, studies of FAP expression using tissue microarrays are conflicting, such that its clinical potential is unclear.

Association of PARP inhibitor treatment on the prevalence and progression of clonal hematopoiesis in patients with advanced prostate cancer.

Poly ADP-ribose polymerase (PARP) inhibitors are approved for the treatment of some men with advanced prostate cancer. Rare but serious side effects include myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).

Prostatectomy in oligometastatic prostate cancer: a call for high-quality evidence.

The systematic review by Saouli et al. investigates the role of radical prostatectomy (RP) in managing oligometastatic prostate cancer (omPCa) [1]. They analyzed the existing literature to assess the oncological and functional outcomes of RP for these patients.

Page 2 of 2879